Caris Life Sciences vs Stipple Bio

Side-by-side comparison of AI visibility scores, market position, and capabilities

Stipple Bio leads in AI visibility (49 vs 22)
Caris Life Sciences logo

Caris Life Sciences

GrowthHealthcare

Precision Oncology

Caris Life Sciences provides comprehensive molecular profiling of tumors to guide cancer treatment decisions, with one of the largest oncology biomarker databases.

AI VisibilityBeta
Overall Score
D22
Category Rank
#2 of 2
AI Consensus
52%
Trend
up
Per Platform
ChatGPT
19
Perplexity
13
Gemini
17

About

Caris Life Sciences is a precision oncology company founded in 1998 and headquartered in Irving, Texas, that provides comprehensive molecular profiling tests used by oncologists to select personalized cancer treatments. The company's flagship test Molecular Intelligence analyzes tumors using whole transcriptome sequencing, whole exome sequencing, and protein expression to identify biomarkers that predict response to specific therapies including targeted drugs and immunotherapies. Caris has built one of the largest real-world oncology molecular databases, with profiles from hundreds of thousands of patient tumors that are used for research, drug development partnerships, and AI model training. The company serves oncologists, cancer centers, and pharmaceutical companies conducting biomarker-driven clinical trials. Caris has raised over $1B and operates CLIA-certified laboratory facilities in Phoenix and Irving. The company's database and AI capabilities have attracted partnerships with pharmaceutical companies seeking to identify patient populations most likely to respond to novel therapies. Caris positions itself at the intersection of clinical diagnostics and drug development infrastructure, generating value both from patient care and from the insights its large clinical database enables.

Full profile
Stipple Bio logo

Stipple Bio

ChallengerBioTech

Precision Oncology

Precision oncology company emerged from stealth Apr 2026 with $100M oversubscribed Series A co-led by RA Capital and a16z Bio; Pointillist platform identifies novel tumor-specific epitopes for antibody-drug conjugates beyond existing ADC targets.

AI VisibilityBeta
Overall Score
C49
Category Rank
#1 of 2
AI Consensus
69%
Trend
up
Per Platform
ChatGPT
46
Perplexity
57
Gemini
59

About

Stipple Bio is a precision oncology company that emerged from stealth in April 2026 with a $100 million oversubscribed Series A. The round was co-led by RA Capital Management, Andreessen Horowitz Bio+Health, and Nextech, with additional participation from GV and Emerson Collective — a top-tier syndicate that signals strong scientific conviction in the platform.

Full profile

AI Visibility Head-to-Head

22
Overall Score
49
#2
Category Rank
#1
52
AI Consensus
69
up
Trend
up
19
ChatGPT
46
13
Perplexity
57
17
Gemini
59
26
Claude
56
33
Grok
57

Key Details

Category
Precision Oncology
Precision Oncology
Tier
Growth
Challenger
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Shared
Precision Oncology

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.